Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments
Lina Quteineh, Frederik Vandenberghe, Nuria Saigi Morgui, Aurelie Delacretaz, Eva Choong, Mehdi Gholam-Rezaee, Pierre Magistretti, Guido Bondolfi, Armin Von Gunten, Martin Preisig, Enrique Castelao, Peter Vollenweider, Gerard Waeber, Murielle Bochud, Zoltan Kutalik, Philippe Conus, Chin B Eap
PHARMACOGENETICS AND GENOMICS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
BACKGROUND: Metabolic syndrome (MetS) associated with psychiatric disorders and psychotropic treatments represents a major health issue. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme that catalyzes tissue regeneration of active cortisol from cortisone. Elevated enzymatic activity of 11β-HSD1 may lead to the development of MetS. METHODS: We investigated the association between seven HSD11B1 gene (encoding 11β-HSD1) polymorphisms and BMI and MetS components in a psychiatric sample treated with potential weight gain-inducing psychotropic drugs (n=478). The polymorphisms that survived Bonferroni correction were analyzed in two independent psychiatric samples (nR1=168, nR2=188) ..View full abstract
Awarded by Swiss National Research Foundation
Awarded by Swiss National Science Foundation
This work has been funded in part by the Swiss National Research Foundation (CBE and PC: 324730_144064). C.B.E. has received research support from Takeda and from the Roche Organ Transplantation Research Foundation in the past 3 years. M.B. is supported by the Swiss School of Public Health Plus (SSPH+). P.V. and G.W. received an unrestricted grant from GlaxoSmithKline to build the CoLaus study. The CoLaus/PsyCoLaus study received financial contributions from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (105993, 118308, 122661, 139468). Z.K. received support from the Leenaards Foundation and the Swiss National Science Foundation (31003A-143914).